Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Eli Lilly and Company (LLY) has launched a Phase 1 trial titled “A Phase 1, Single-Blinded, Single-Ascending Dose Study to Evaluate the Safety and Tolerability of a Single Dose of LY3971297 in Participants With HFpEF and Participants With HFrEF.” The study aims to test safety, side effects, and basic drug behavior in people with different types of heart failure, a large and growing market.
Intervention/Treatment: The study tests LY3971297, an experimental heart failure drug, given either under the skin or through a vein. Participants receive a single dose of LY3971297 or a placebo, with the goal of seeing how well patients tolerate the drug and how their bodies handle it.
Study Design: This is a randomized, single-blind, placebo-controlled trial, meaning patients do not know if they are getting LY3971297 or a placebo, but researchers do. The design uses parallel groups and focuses mainly on treatment safety and basic effects rather than measuring long-term outcomes like survival or hospitalizations.
Study Timeline: The study was first submitted on April 17, 2026, and is listed as not yet recruiting, so no patients have been treated yet. The latest update was filed on May 20, 2026, and primary and final completion dates are not yet posted, which is typical for an early-stage trial.
Market Implications: For investors, this update signals that Lilly is quietly expanding its cardiovascular pipeline beyond its well-known diabetes and obesity franchises. Any future success in heart failure could support LLY’s long-term growth story and help it compete with peers such as Novartis and AstraZeneca, although near-term earnings impact remains limited at this early stage.
Market Implications (cont.): Positive safety data later on could lift sentiment around Lilly’s diversification into cardiology, while setbacks would likely have only a modest effect given the company’s broader portfolio. The study is ongoing in its setup phase, with more details available on the ClinicalTrials.gov portal under NCT07547540.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.